Equillium, Inc. (EQ) vs Neumora Therapeutics, Inc. Common Stock (NMRA)

A side-by-side comparison of Equillium, Inc. and Neumora Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Equillium, Inc.

$91M

$1.44HealthcareDelayed quote: Oct 6, 2026, 1:04 PM EDT

NMRA

Neumora Therapeutics, Inc. Common Stock

$90M

$0.48HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT

Total return — EQ vs NMRA

growth of $100 · dividends reinvested · last 3y

EQ +85.8% (+22.9%/yr)NMRA -96.8% (-68.1%/yr)EQ compounded faster over this window

Log scale — wide-divergence pair

EQ NMRA

EQ vs NMRA: by the numbers

•EQ is the larger company ($91M vs $90M market cap).

Metrics side by side

Valuation

Metric	EQ	NMRA
P/B ratio	1.62	2.01

Profitability

Metric	EQ	NMRA
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-32.15%	-477.87%
ROIC	-34.10%	-216.05%

Growth (annualized)

Metric	EQ	NMRA
Total return CAGR (5Y)	-26.99%	N/A

Go deeper

Full EQ analysis Full NMRA analysis Interactive comparison tool

Dig into the metrics

Equillium ROE Neumora Therapeutics, Inc. Common Stock ROE Equillium operating margin Neumora Therapeutics, Inc. Common Stock operating margin Equillium revenue growth Neumora Therapeutics, Inc. Common Stock revenue growth Equillium free cash flow Neumora Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.